Werewolf Therapeutics, Inc. Reports Q3 Loss, Misses Revenue Estimates - Yahoo Movies UK

HOWL Stock  USD 1.48  0.16  9.76%   
About 61% of Werewolf Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Werewolf Therapeutics suggests that many traders are alarmed. Werewolf Therapeutics' investing sentiment shows overall attitude of investors towards Werewolf Therapeutics.
  
Werewolf Therapeutics, Inc. Reports Q3 Loss, Misses Revenue Estimates Yahoo Movies UK

Read at news.google.com
Google News at Macroaxis
  

Werewolf Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Werewolf Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Werewolf Therapeutics Fundamental Analysis

We analyze Werewolf Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Werewolf Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Werewolf Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Shares Owned By Institutions

Shares Owned By Institutions Comparative Analysis

Werewolf Therapeutics is currently under evaluation in shares owned by institutions category among its peers. Shares Owned by Institutions show the percentage of the outstanding shares of stock issued by a company that is currently owned by other institutions such as asset management firms, hedge funds, or investment banks. Many investors like investing in companies with a large percentage of the firm owned by institutions because they believe that larger firms such as banks, pension funds, and mutual funds, will invest when they think that good things are going to happen.

Werewolf Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Werewolf Therapeutics stock to make a market-neutral strategy. Peer analysis of Werewolf Therapeutics could also be used in its relative valuation, which is a method of valuing Werewolf Therapeutics by comparing valuation metrics with similar companies.

Peers

Werewolf Therapeutics Related Equities

CSBRChampions Oncology   7.97   
0%
81.0%
STOKStoke Therapeutics   1.71   
0%
17.0%
DSGNDesign Therapeutics   0.67   
0%
6.0%
MNOVMediciNova   0.47   
0%
4.0%
EWTXEdgewise Therapeutics   0.53   
5.0%
0%
CELCCelcuity LLC   0.83   
8.0%
0%
MOLNMolecular Partners   1.51   
15.0%
0%
IKNAIkena Oncology   4.32   
44.0%
0%
VORVor Biopharma   4.49   
46.0%
0%
THRDThird Harmonic   4.67   
47.0%
0%
ACETAdicet Bio   6.25   
64.0%
0%
CGEMCullinan Oncology   6.27   
64.0%
0%
ACRVAcrivon Therapeutics,   7.21   
73.0%
0%
GLUEMonte Rosa   7.40   
75.0%
0%
PASGPassage Bio   8.96   
91.0%
0%
CCCCC4 Therapeutics   9.63   
98.0%
0%
ANEBAnebulo Pharmaceuticals   9.76   
100.0%
0%
When determining whether Werewolf Therapeutics is a strong investment it is important to analyze Werewolf Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Werewolf Therapeutics' future performance. For an informed investment choice regarding Werewolf Stock, refer to the following important reports:
Check out Werewolf Therapeutics Hype Analysis, Werewolf Therapeutics Correlation and Werewolf Therapeutics Performance.
For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.
You can also try the Competition Analyzer module to analyze and compare many basic indicators for a group of related or unrelated entities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.52)
Revenue Per Share
0.082
Quarterly Revenue Growth
(0.86)
Return On Assets
(0.26)
Return On Equity
(0.62)
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.